Activation of Hepatocyte Growth Factor Activator Zymogen (pro-HGFA) by Human Kallikrein 1-related Peptidases
Overview
Affiliations
Hepatocyte growth factor activator (HGFA) is a serine protease and a potent activator of prohepatocyte growth factor/scatter factor (pro-HGF/SF), a multifunctional growth factor that is critically involved in tissue morphogenesis, regeneration, and tumor progression. HGFA circulates as a zymogen (pro-HGFA) and is activated in response to tissue injury. Although thrombin is considered to be an activator of pro-HGFA, alternative pro-HGFA activation pathways in tumor microenvironments remain to be identified. In this study, we examined the effects of kallikrein 1-related peptidases (KLKs), a family of extracellular serine proteases, on the activation of pro-HGFA. Among the KLKs examined (KLK2, KLK3, KLK4 and KLK5), we identified KLK4 and KLK5 as novel activators of pro-HGFA. Using N-terminal sequencing, the cleavage site was identified as the normal processing site, Arg407-Ile408. The activation of pro-HGFA by KLK5 required a negatively charged substance such as dextran sulfate, whereas KLK4 could process pro-HGFA without dextran sulfate. KLK5 showed more efficient pro-HGFA processing than KLK4, and was expressed in 50% (13/25) of the tumor cell lines examined. HGFA processed by these KLKs efficiently activated pro-HGF/SF, and led to cellular scattering and invasion in vitro. The activities of both KLK4 and KLK5 were strongly inhibited by HGFA inhibitor type 1, an integral membrane Kunitz-type serine protease inhibitor that inhibits HGFA and other pro-HGF/SF-activating proteases. These data suggest that KLK4 and KLK5 mediate HGFA-induced activation of pro-HGF/SF within tumor tissue, which may thereafter trigger a series of events leading to tumor progression via the MET receptor.
Mahoney M, Helander J, Kooner A, Norman M, Damalanka V, De Bona P Protein Sci. 2024; 33(8):e5110.
PMID: 39073183 PMC: 11284329. DOI: 10.1002/pro.5110.
Inhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer.
Jones V, Graves-Deal R, Cao Z, Bogatcheva G, Ramirez M, Harmych S Cell Mol Life Sci. 2024; 81(1):28.
PMID: 38212428 PMC: 10784391. DOI: 10.1007/s00018-023-05071-5.
HGFAC is a ChREBP-regulated hepatokine that enhances glucose and lipid homeostasis.
Sargsyan A, Doridot L, Hannou S, Tong W, Srinivasan H, Ivison R JCI Insight. 2022; 8(1).
PMID: 36413406 PMC: 9870088. DOI: 10.1172/jci.insight.153740.
Remodelling of the tumour microenvironment by the kallikrein-related peptidases.
Srinivasan S, Kryza T, Batra J, Clements J Nat Rev Cancer. 2022; 22(4):223-238.
PMID: 35102281 DOI: 10.1038/s41568-021-00436-z.
Huang H, Chen P, Chu S, Lee M, Huang C, Chu T Neoplasia. 2021; 23(11):1123-1136.
PMID: 34688971 PMC: 8550993. DOI: 10.1016/j.neo.2021.09.006.